Saponin-based adjuvants (SBAs) are promising new adjuvants that stand out as they not only enforce CD4 + T cell-mediated immunity and antibody responses, but also induce an unprecedented level of antigen cross-presentation by dendritic cells (DC) and subsequent CD8 + T cell activation. This was published in Cellular and Molecular Life Sciences.
Lisa Huis in ‘t Veld, Nataschja Ho and colleagues from the team of Gosse Adema at the Radiotherapy & OncoImmunology (ROI) lab, theme Cancer development and immune defense discovered that SBA's ability to boost cross-presentation depends on the induction of lipid bodies. Moreover, the MHCII-low CD11b-high DC subset was identified to be most responsive to SBA-induced cross-presentation.
The aim is to further unravel the mechanisms behind the induction of DC cross-presentation by SBAs. Here we show that SBAs specifically induce the PKR-like Endoplasmic Reticulum kinase (PERK) pathway and that SBA-induced DC cross-presentation is dependent on activation of the PERK pathway. PERK activation and lipid body formation are both crucial for SBA-induced cross-presentation and PERK inhibition has little or no effect on SBA-induced lipid body formation. SBA's responsiveness, lipid body formation and PERK activation are specific for the MHCII-low CD11b-high DCs.
These findings contribute to understanding the pathways involved in SBA-induced cross-presentation and immune activation which will ultimately lead to the development of vaccines with improved efficiency and safety.
Related news items
A single protein complex balances the very first lineage decision of cells in human: towards foetus or placenta21 June 2022
The international group of researchers spearheaded by Dick Zijlmans and Hendrik Marks together with colleagues from KU Leuven, examined which proteins are associated with the chromatin and how this affects gene transcription.read more
Dutch Society of Clinical Chemistry Science & Innovation Award for the team of Hans Jacobs14 June 2022
The team of Hans Jacobs pioneers on the development of personalized diagnostics to measure minimal residual disease in patients with multiple myeloma.read more
European grants for groundbreaking Radboudumc research Professors Roshan Cools and Peter Friedl receive ERC Advanced Grant26 April 2022
The European Research Council (ERC) is awarding grants to Roshan Cools and Peter Friedl, both professors at Radboudumc. While Cools will investigate how brains control behaviour in (stressful) situations, Friedl will work on developing a new cancer therapy.read more
ERC Proof of Concept Grant for Martijn Verdoes8 March 2022
Martijn Verdoes, group leader Chemical Immunology at the department of Tumor Immunology, has been awarded an ERC Proof of Concept (PoC) Grant. The ERC PoC Grants are designed to support ERC grantees with the commercial or societal application of the results of their funded research.read more
DeepRank: a deep learning framework for data mining 3D protein-protein interfaces8 December 2021
Li Xue and colleagues recently published ''DeepRank, a deep learning framework for data mining 3D protein-protein structures'' in Nature Communications.read more